Table 1 Patient characteristics
Characteristics | whole period | phase A | phase B | phase C | phase D | p value |
|---|---|---|---|---|---|---|
sex | ||||||
female | 52 | 16 | 12 | 17 | 7 | 0.059 |
male | 72 | 20 | 6 | 26 | 20 | |
age (years) | 15–75 (52.0) | 25–73 (56.5) | 19–71 (46.5) | 18–75 (51) | 15–70 (52) | 0.763 |
> median(53–75) | 59 | 19 | 8 | 19 | 13 | 0.890 |
< median(15–52) | 65 | 17 | 10 | 24 | 14 | |
neutropenia (days) | 12–179 (61) | 15–150 (65.5) | 12–168 (57.0) | 18–122 (58.0) | 12–179 (53.0) | 0.520 |
> median(62–179) | 60 | 22 | 8 | 19 | 11 | 0.342 |
< median(12–61) | 64 | 14 | 10 | 24 | 16 | |
lineage | ||||||
AML | 102 | 31 | 15 | 33 | 23 | 0.729 |
ALL | 22 | 5 | 3 | 10 | 4 | |
prophylaxis | ||||||
FLCZ only | 69 | 22 | 14 | 22 | 11 | 0.082 |
mold-active agent | 55 | 14 | 4 | 21 | 16 | |
ITCZ | 6 | 3 | 0 | 1 | 2 | |
VRCZ | 5 | 1 | 1 | 1 | 2 | |
MCFG | 50 | 12 | 3 | 21 | 14 | |
CPFG | 1 | 0 | 0 | 0 | 1 | |
AMB | 1 | 1 | 0 | 0 | 0 | |
L-AMB | 5 | 0 | 1 | 3 | 1 | |
treatment response after induction chemotherapy | ||||||
CR | 76 | 21 | 11 | 24 | 20 | 0.677 |
CRi | 3 | 1 | 1 | 1 | 0 | |
non-CR | 45 | 14 | 6 | 18 | 7 | |
median follow-up of event free survivors (days) | 139.0 (27–330) | 132.5 (29–236) | 149.0 (27–330) | 139.0 (42–261) | 135.0 (41–272) | 0.963 |